Executive Summary
Overnight SEC filings from December 31, 2025, reveal a surge in routine end-of-year disclosures, dominated by neutral sentiment 8-Ks focused on officer changes, material agreements, Regulation FD updates, and shareholder votes, with limited quantifiable details across the board. Critical outliers include a high-materiality governance shakeup involving control changes (Unknown Company #4) and a bearish delisting notice (Modular Medical #25), signaling potential volatility in small-cap biotech and speculative names. Overall market impact remains low, but clusters in biotech/pharma and leadership transitions warrant caution for portfolios heavy in micro-caps, with minimal broad alpha opportunities amid disclosure opacity.
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from December 29, 2025.
Investment Signals(4)
- ▲
Modular Medical delisting notice signals severe liquidity and compliance risks [BEARISH] - Modular Medical
- ▲
Multiple material definitive agreements (Riot Platforms, Imunon, BioAtla) hint at strategic pivots or financing without disclosed negatives [BULLISH] - Riot Platforms, Imunon, BioAtla
- ▲
Cluster of officer changes across financials and diversified holdings may indicate proactive succession planning [NEUTRAL-to-BULLISH] - Capital Bancorp, Compass Diversified, Cable One
- ▲
Changes in control and security holder rights modifications elevate uncertainty in unknown filer [BEARISH] - Unknown Company #4
Risk Flags(4)
- ▼
Modular Medical's critical delisting risk (Item 3.01) poses immediate share price downside and OTC trading uncertainty
- ▼
Unknown Company #4's high-materiality governance overhaul (control changes, bylaws amendments) could trigger ownership disputes or dilution
- ▼
Recurrent lack of details in medium/high materiality filings (e.g., Riot, Profound Medical) heightens information asymmetry and potential for post-open surprises
- ▼
Biotech cluster (10+ filings) with undisclosed agreements raises sector-wide regulatory scrutiny risks on unregistered securities sales
Opportunities(3)
- ◆
Strategic M&A or financing catalysts in biotech via Item 1.01 disclosures (Emmaus, Imunon, BioAtla) for event-driven longs if details confirm partnerships
- ◆
Officer appointment signals in financials (Capital Bancorp, Universal Health) as entry points for governance-improved names
- ◆
Riot Platforms' agreement entry/termination combo may signal portfolio optimization in crypto mining space for tactical trades
Sector Themes(3)
- ◆
Biotech/Pharma dominance (Oramed, Profound, Vanda, Verastem, etc.) with frequent Reg FD, other events, and deals points to year-end pipeline or funding updates amid neutral sentiment
- ◆
Leadership churn across sectors (6+ officer changes in financials, diversified, healthcare) reflects routine Q4 transitions but clusters suggest broader talent mobility
- ◆
Governance and control events (Unknown #4, Groupon) alongside shareholder votes indicate heightened M&A and SPAC unwind activity in small-caps
Watch List(4)
- 👁
Modular Medical - Delisting trajectory demands pre-open position review and short opportunities
0001140361-25-046926) - Control changes and rights mods require full filing review for takeover plays
- 👁
Riot Platforms & Imunon - Material agreements for potential deal announcements driving volatility
- 👁
Biotech cluster (Profound Medical, BioAtla, Emmaus) - Cross-correlated unregistered equity sales may signal sector funding wave
Filing Analyses(30)
31-12-2025
Oramed Pharmaceuticals Inc. filed a Form 8-K on December 31, 2025, reporting under Item 8.01 Other Events. Accession number: 0001012975-25-000992. Filing size: 159 KB. No specific event details, transactions, or financial data disclosed in the provided filing summary.
31-12-2025
Profound Medical Corp. filed a Form 8-K on December 31, 2025 (AccNo: 0001104659-25-125344), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the core event, transaction value, or financial impacts provided in the summary. All quantitative data, named entities beyond the filer, and further details are NOT_DISCLOSED.
31-12-2025
News Corp filed a Form 8-K on December 31, 2025 (AccNo: 0001564708-25-000612, Size: 400 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure with no quantified impacts mentioned.
31-12-2025
The company filed a multi-item Form 8-K on December 31, 2025 (AccNo: 0001140361-25-046926, Size: 937 KB), reporting entry into a material definitive agreement (Item 1.01), material modifications to rights of security holders (Item 3.03), changes in control of registrant (Item 5.01), changes in directors/officers or compensatory arrangements (Item 5.02), amendments to articles of incorporation or bylaws (Item 5.03), amendments to code of ethics (Item 5.05), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No transaction values, share counts, financial metrics, named entities, or specific details are disclosed in the provided filing summary. This indicates significant corporate governance and control events requiring further review.
31-12-2025
GlobalTech Corp filed a Form 8-K on December 31, 2025 (AccNo: 0001477932-25-009262, Size: 133 KB), reporting Item 5.07: Submission of Matters to a Vote of Security Holders. Sector not specified. No details on specific matters voted on, outcomes, numerical values, or other events disclosed.
31-12-2025
Amerant Bancorp Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001734342-25-000082, Size: 1 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the core event, transactions, financial metrics, or exhibits are disclosed in the provided filing summary. This appears to be a voluntary disclosure of material information with attached exhibits.
31-12-2025
Vanda Pharmaceuticals Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001628280-25-059155, Size: 251 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.
31-12-2025
Riot Platforms, Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001104659-25-125324, Size: 652 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 1.02 termination of a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No details on the agreements, transaction values, parties involved, or financial impacts are provided in the filing summary.
31-12-2025
Verastem, Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001104659-25-125309, Size: 234 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other specifics are disclosed in the provided filing summary. This is a multi-item filing with no quantitative data available.
31-12-2025
Capital Bancorp Inc disclosed an officer change via Form 8-K filed on December 31, 2025 (AccNo: 0001419536-25-000140, size 8 MB), under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements). Additional Items include 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No specific details on officers, positions, reasons, or quantitative data provided.
31-12-2025
Soho House & Co Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001140361-25-046916), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific other events or the nature of the financial statements/exhibits are disclosed in the provided filing summary. All quantitative data including transaction values, share counts, percentages, and financial metrics are NOT_DISCLOSED.
31-12-2025
Emmaus Life Sciences, Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001213900-25-126728), reporting Items 1.01 (Entry into a Material Definitive Agreement), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No details on the agreement, events, transaction value, or financial impacts are disclosed in the provided information. This is a multi-item mandatory filing with sector not specified.
31-12-2025
IDACORP INC filed a Form 8-K on December 31, 2025 (AccNo: 0001057877-25-000091, size: 200 KB) reporting under Item 8.01 Other Events. No details on the specific event, transaction, or financial impacts are provided in the filing summary. Sector is not specified.
31-12-2025
NETSTREIT Corp. filed a Form 8-K on December 31, 2025 (AccNo: 0001628280-25-059149, Size: 176 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event, transaction details, financial metrics, or quantitative data are explicitly stated in the provided filing summary. Sector is not specified.
31-12-2025
SBC Medical Group Holdings Inc filed a Form 8-K on December 31, 2025 (AccNo: 0001493152-25-029699, Size: 278 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on the disclosures, events, transactions, financial statements, or exhibits are provided in the filing summary. Sector is not specified.
31-12-2025
Streamex Corp. filed a Form 8-K on December 31, 2025 (AccNo: 0001493152-25-029675, size: 252 KB) reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), submission of matters to a vote of security holders under Item 5.07, and financial statements and exhibits under Item 9.01. Event type is Officer Change from US SEC source. Sector not specified.
31-12-2025
Compass Diversified Holdings filed an 8-K on 2025-12-31 (AccNo: 0001345126-25-000095, Size: 232 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, appointment/resignation status, reasons, or any quantitative data are provided in the filing summary. Sector not specified.
31-12-2025
Cable One, Inc. disclosed an officer change event via Form 8-K filed on December 31, 2025 (AccNo: 0000950157-25-001040, size 858 KB), covering Item 5.02 (Departure of Directors or Certain Officers; Election/Appointment of Officers; Compensatory Arrangements), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on positions, individuals, reasons, or quantitative impacts are provided in the available summary. All leadership, governance, and financial specifics are NOT_DISCLOSED.
31-12-2025
Sonim Technologies Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001493152-25-029706, Size: 212 KB), reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on votes, outcomes, numerical data, or other events are disclosed in the provided filing information. This appears to be a routine disclosure related to shareholder meeting matters.
31-12-2025
BioAtla, Inc. filed a Form 8-K on 2025-12-31 (AccNo: 0001193125-25-337646, Size: 186 KB) reporting multiple items: Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing for material events, but no specific details, transaction values, parties, or financial impacts are disclosed in the provided summary. Sector is not specified.
31-12-2025
Axsome Therapeutics, Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001193125-25-337644), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, transactions, or exhibits are disclosed in the provided filing summary. No quantitative data, named entities beyond the filer, or financial impacts are mentioned.
31-12-2025
Aspira Women's Health Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0000926617-25-000014, Size: 10 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with sector not specified. No core event details, financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.
31-12-2025
Groupon, Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001628280-25-059158), reporting entry into a material definitive agreement under Item 1.01, departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements under Item 5.02, and financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details, dollar values, names, or transaction sizes disclosed in the provided summary. Sector is not specified.
31-12-2025
TransDigm Group INC filed a Form 8-K on December 31, 2025 (AccNo: 0001260221-25-000084, Size: 392 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.
31-12-2025
Modular Medical, Inc. filed an 8-K on December 31, 2025 (AccNo: 0001213900-25-126825, Size: 207 KB), disclosing under Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. This indicates a delisting event from the US market. Sector not specified.
31-12-2025
Eightco Holdings Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001493152-25-029714, Size: 228 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the core event, transaction values, financial metrics, or exhibits are disclosed in the provided filing summary. All quantitative data and event specifics are NOT_DISCLOSED.
31-12-2025
Imunon, Inc. filed a Form 8-K on December 31, 2025 (AccNo: 0001493152-25-029711, Size: 953 KB), disclosing under Item 1.01 entry into a Material Definitive Agreement, under Item 8.01 Other Events, and under Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, events, or exhibits provided in the available information. Sector is not specified.
31-12-2025
Westin Acquisition Corp filed an 8-K on December 31, 2025 (AccNo: 0001213900-25-126818, Size: 259 KB), disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits related to a Merger/Acquisition event. No specific deal structure, parties involved, valuation, financial terms, or strategic rationale are detailed in the provided filing summary. Sector is not specified.
31-12-2025
Global Interactive Technologies, Inc. filed an 8-K on December 31, 2025 (AccNo: 0001213900-25-126813), reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No details on specific matters, vote results, or numerical data are provided in the filing summary. This is a routine disclosure of shareholder meeting outcomes.
31-12-2025
Universal Health Services Inc filed a Form 8-K on December 31, 2025 (AccNo: 0001193125-25-337662, Size: 297 KB) disclosing an officer change under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific names, positions, reasons, or quantitative data are disclosed in the provided filing summary.
Get daily alerts with 4 investment signals, 4 risk alerts, 3 opportunities and full AI analysis of all 30 filings
🇺🇸 More from United States
View all →March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC
March 24, 2026
US Corporate Distress Financial Stress SEC Filings — March 24, 2026
US Corporate Distress Financial Stress SEC Filings